PLUR
What one share of Pluri holds
Biological Products, (No Diagnostic Substances)
We are a biotechnology company leveraging our proprietary 3D cell expansion platform, which is supported by an in-house, industrial-scale cell manufacturing facility and operates in accordance with Good Manufacturing Practice (“GMP”) standards on a self-declared basis.
Pluri’s numbers from its SEC filings, divided by its shares. Results cover the latest fiscal year to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.10 |
|---|---|
| Profit | −$2.44 |
| Capex (buildings and equipment) | $0.07 |
| Free cash flow | −$2.08 |
| Cash and investments | $0.33 |
| Book value | −$2.13 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2017 | — | −$25.45 | $0.35 | −$20.12 | — | — |
| 2018 | $0.04 | −$19.74 | $0.26 | −$16.41 | — | — |
| 2019 | $0.04 | −$22.90 | $0.15 | −$19.26 | — | — |
| 2020 | $0.01 | −$12.82 | $0.12 | −$11.71 | — | — |
| 2021 | — | −$14.19 | $0.11 | −$8.90 | — | — |
| 2022 | $0.06 | −$10.25 | $0.07 | −$9.14 | — | — |
| 2023 | $0.06 | −$6.18 | $0.06 | −$5.05 | — | — |
| 2024 | $0.06 | −$3.99 | $0.06 | −$3.50 | — | $0.02 |
| 2025 | $0.21 | −$3.56 | $0.26 | −$3.13 | — | −$0.87 |
| 2026 | $0.10 | −$2.44 | $0.07 | −$2.08 | — | −$2.13 |